Pneumonia Therapeutics Global Market Report 2025

Description

Pneumonia therapeutics encompass treatments and medications designed to manage and treat pneumonia, a lung infection caused by bacteria, viruses, or fungi. These therapeutics work by targeting the underlying pathogens, reducing inflammation, and improving respiratory function. Treatments include antibiotics for bacterial pneumonia, antiviral drugs for viral pneumonia, and antifungal agents for fungal infections.

The main products in pneumonia therapeutics include drugs, vaccines, and oxygen therapy. Pneumonia drugs address the root cause by using antibiotics, antivirals, antifungals, and supportive treatments such as oxygen therapy. The infections treated include hospital-acquired pneumonia (HAP), community-acquired pneumonia (CAP), and ventilator-associated pneumonia (VAP). Routes of administration include oral, parenteral, and other methods, with end users spanning hospitals, home care, specialty clinics, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The pneumonia therapeutics market research report is one of a series of new reports from The Business Research Company that provides pneumonia therapeutics market statistics, including the pneumonia therapeutics industry's global market size, regional shares, competitors with a pneumonia therapeutics market share, detailed pneumonia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the pneumonia therapeutics industry. This pneumonia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pneumonia therapeutics market size has grown rapidly in recent years. It will grow from $10.35 billion in 2024 to $11.46 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increase in prevalence of drug-resistant strains, rise in awareness of pneumonia prevention, growth in elderly and immunocompromised populations, expanded vaccination programs, and improved healthcare infrastructure.

The pneumonia therapeutics market size is expected to see rapid growth in the next few years. It will grow to $17.11 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to increasing antibiotic-resistant strains, growing prevalence of pneumonia in aging populations, expansion of telemedicine for early diagnosis, rising healthcare expenditures in emerging markets, increasing funding for infectious disease research, and heightened awareness campaigns. Major trends in the forecast period include development of monoclonal antibodies, adoption of inhalable antibiotics, innovation in mRNA-based vaccines, AI-driven diagnostic tools, adoption of host-targeted therapies, novel immunomodulators, and advancements in rapid point-of-care diagnostic platforms.

The forecast of 10.6% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. treatment of severe pneumonia by inflating prices of rapid multiplex Polymerase Chain Reaction panels panels and IV antibiotic formulations developed in India and Spain, resulting in delayed appropriate antibiotic initiation and higher infectious disease management costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of pneumonia is expected to drive the growth of the pneumonia therapeutics market. Pneumonia is a lung infection that causes inflammation in the air sacs, leading to symptoms such as cough, fever, and difficulty breathing. The rising incidence of pneumonia is attributed to factors including aging populations, air pollution, smoking, weakened immune systems, antimicrobial resistance, and the spread of respiratory infections such as COVID-19 and influenza. Pneumonia therapeutics are designed to combat the infection's underlying cause whether bacterial, viral, or fungal through targeted medications while supporting recovery with oxygen therapy, anti-inflammatory drugs, and symptom management. For example, in January 2023, the National Center for Biotechnology Information reported that pneumonia affects approximately 120 million people worldwide each year, resulting in around 1.3 million deaths. Nearly 80% of pediatric pneumonia fatalities occur in children under two years old in developing nations. As a result, the growing prevalence of pneumonia is fueling the expansion of the pneumonia therapeutics market.

Leading companies in the pneumonia therapeutics market are focusing on innovative drug formulations and treatment methods to address antibiotic resistance and enhance patient outcomes. Antibiotic drugs play a crucial role in treating bacterial infections, including pneumonia. In June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, collaborated with Cipla Limited, another India-based pharmaceutical firm, to introduce cefepime-enmetazobactam. This antibiotic combination is designed to treat complex infections, such as urinary tract infections (UTIs) and pneumonia, particularly those resistant to other medications. By combating bacterial resistance, it ensures more effective treatment while reducing the need for stronger antibiotics.

In August 2022, GSK plc, a UK-based pharmaceutical company, acquired Affinivax Inc. for an undisclosed amount. This acquisition allows Affinivax to continue its work under GSK's leadership, focusing on next-generation pneumococcal vaccines. Affinivax Inc. is a US-based biopharmaceutical company specializing in developing vaccines to prevent pneumonia and other diseases caused by Streptococcus pneumoniae. This strategic move strengthens GSK's pneumonia vaccine portfolio, reinforcing its position in the market.

Major players in the pneumonia therapeutics market are Pfizer Inc., Roche AG, Merck & Co. Inc., AbbVie Inc, Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Shionogi & Co. Ltd, Lupin Limited, Swedish Orphan Biovitrum AB, Nabriva Therapeutics plc, TaiGen Biotechnology Co. Ltd, Aridis Pharmaceuticals Inc., and Tergene Biotech Limited.

North America was the largest region in the pneumonia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pneumonia therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pneumonia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pneumonia therapeutics market consists of revenues earned by entities by providing services such as chest X-rays, blood tests, sputum culture, oxygen supplementation, mechanical ventilation, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The pneumonia therapeutics market also includes sales of pneumococcal vaccines, antibiotics, nebulizers, and inhalers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values, that is, revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pneumonia Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pneumonia therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pneumonia therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pneumonia therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product: Drugs; Vaccine; Oxygen Therapy
2) By Infection: Hospital-Acquired Pneumonia (HAP); Community-Acquired Pneumonia (CAP); Ventilator-Associated Pneumonia (VAP)
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By End Use: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Drugs: Antibiotics; Antiviral Drugs; Antifungal Drugs; Corticosteroids; Other Drugs
2) By Vaccine: Pneumococcal Vaccines; Haemophilus Influenzae Type B (Hib) Vaccines; Influenza Vaccines; Other Vaccines
3) By Oxygen Therapy: High-Flow Nasal Cannula (HFNC); Non-Invasive Ventilation (NIV); Mechanical Ventilation; Other Oxygen Therapies
Companies Mentioned: Pfizer Inc.; Roche AG; Merck & Co. Inc.; AbbVie Inc; Bayer AG; Sanofi S.A.; AstraZeneca PLC; Abbott Laboratories; Novartis AG; GSK plc; Eli Lilly and Company; Astellas Pharma Inc.; Eisai Co. Ltd.; Sun Pharmaceutical Industries Ltd.; Cipla Inc.; Hikma Pharmaceuticals PLC; Shionogi & Co. Ltd; Lupin Limited; Swedish Orphan Biovitrum AB; Nabriva Therapeutics plc; TaiGen Biotechnology Co. Ltd; Aridis Pharmaceuticals Inc.; Tergene Biotech Limited.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34124u

1. Executive Summary

2. Pneumonia Therapeutics Market Characteristics

3. Pneumonia Therapeutics Market Trends And Strategies

4. Pneumonia Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Pneumonia Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Pneumonia Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Pneumonia Therapeutics Market Growth Rate Analysis
5.4. Global Pneumonia Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Pneumonia Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Pneumonia Therapeutics Total Addressable Market (TAM)

6. Pneumonia Therapeutics Market Segmentation

6.1. Global Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Drugs
Vaccine
Oxygen Therapy
6.2. Global Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital-Acquired Pneumonia (HAP)
Community-Acquired Pneumonia (CAP)
Ventilator-Associated Pneumonia (VAP)
6.3. Global Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Route Of Administrations
6.4. Global Pneumonia Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End Users
6.5. Global Pneumonia Therapeutics Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antibiotics
Antiviral Drugs
Antifungal Drugs
Corticosteroids
Other Drugs
6.6. Global Pneumonia Therapeutics Market, Sub-Segmentation Of Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pneumococcal Vaccines
Haemophilus Influenzae Type B (Hib) Vaccines
Influenza Vaccines
Other Vaccines
6.7. Global Pneumonia Therapeutics Market, Sub-Segmentation Of Oxygen Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
High-Flow Nasal Cannula (HFNC)
Non-Invasive Ventilation (NIV)
Mechanical Ventilation
Other Oxygen Therapies

7. Pneumonia Therapeutics Market Regional And Country Analysis

7.1. Global Pneumonia Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Pneumonia Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pneumonia Therapeutics Market

8.1. Asia-Pacific Pneumonia Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pneumonia Therapeutics Market

9.1. China Pneumonia Therapeutics Market Overview
9.2. China Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pneumonia Therapeutics Market

10.1. India Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pneumonia Therapeutics Market

11.1. Japan Pneumonia Therapeutics Market Overview
11.2. Japan Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pneumonia Therapeutics Market

12.1. Australia Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pneumonia Therapeutics Market

13.1. Indonesia Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pneumonia Therapeutics Market

14.1. South Korea Pneumonia Therapeutics Market Overview
14.2. South Korea Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pneumonia Therapeutics Market

15.1. Western Europe Pneumonia Therapeutics Market Overview
15.2. Western Europe Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pneumonia Therapeutics Market

16.1. UK Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pneumonia Therapeutics Market

17.1. Germany Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pneumonia Therapeutics Market

18.1. France Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pneumonia Therapeutics Market

19.1. Italy Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pneumonia Therapeutics Market

20.1. Spain Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pneumonia Therapeutics Market

21.1. Eastern Europe Pneumonia Therapeutics Market Overview
21.2. Eastern Europe Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pneumonia Therapeutics Market

22.1. Russia Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pneumonia Therapeutics Market

23.1. North America Pneumonia Therapeutics Market Overview
23.2. North America Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pneumonia Therapeutics Market

24.1. USA Pneumonia Therapeutics Market Overview
24.2. USA Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pneumonia Therapeutics Market

25.1. Canada Pneumonia Therapeutics Market Overview
25.2. Canada Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pneumonia Therapeutics Market

26.1. South America Pneumonia Therapeutics Market Overview
26.2. South America Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pneumonia Therapeutics Market

27.1. Brazil Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pneumonia Therapeutics Market

28.1. Middle East Pneumonia Therapeutics Market Overview
28.2. Middle East Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pneumonia Therapeutics Market

29.1. Africa Pneumonia Therapeutics Market Overview
29.2. Africa Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pneumonia Therapeutics Market Competitive Landscape And Company Profiles

30.1. Pneumonia Therapeutics Market Competitive Landscape
30.2. Pneumonia Therapeutics Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Pneumonia Therapeutics Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. AstraZeneca PLC
31.3. Abbott Laboratories
31.4. Novartis AG
31.5. GSK plc
31.6. Eli Lilly and Company
31.7. Astellas Pharma Inc.
31.8. Eisai Co. Ltd.
31.9. Sun Pharmaceutical Industries Ltd.
31.10. Cipla Inc.
31.11. Hikma Pharmaceuticals PLC
31.12. Shionogi & Co. Ltd
31.13. Lupin Limited
31.14. Swedish Orphan Biovitrum AB
31.15. Nabriva Therapeutics plc

32. Global Pneumonia Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pneumonia Therapeutics Market

34. Recent Developments In The Pneumonia Therapeutics Market

35. Pneumonia Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Pneumonia Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Pneumonia Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Pneumonia Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer